Clinical trial Recruiting at 1 site Interventional Ages 18 to 71

Tamsulosin 0.4 mg with Tadalafil 5 mg versus 2.5 mg to reduce symptoms from ureteral stents

Official title: Safety and Efficacy of Combination of Tamsulosin 0.4 mg Plus Tadalafil 5mg Versus 2.5 mg for Ureteric Stent Related Symptoms

Run by Ain Shams University · NCT07562282 · Data updated 2026-11-12

This will test whether adding Tadalafil at 5 mg or 2.5 mg to Tamsulosin 0.4 mg better reduces stent-related symptoms for adults with a double-J ureteral stent after stone removal.

More Kidney Stone trials

Quick facts

Study typeInterventional
Ages18 Years to 71 Years
SexAll
Enrollment140 (estimated)
SponsorAin Shams University
Academic / other
Drugs / interventionsradiation
Locations1 site (Cairo, Abbasia)
StatusRecruiting
StartedDecember 1, 2025
Main results expectedJuly 1, 2026
Study endsJuly 10, 2026
Registry record updatedMay 1, 2026
Trial IDNCT07562282 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 years old who have a polyurethane double-J stent placed after endoscopic kidney stone removal and who do not meet any exclusion criteria are appropriate candidates.

Probably not a fit

Patients with diabetes, renal dysfunction, solitary kidney, prior pelvic or lower urinary tract surgery, active cancer, significant cardiac or neurological disease, recent pelvic radiation, or those taking excluded medications are unlikely to be eligible or to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with polyurethane double-J stents placed after endoscopic stone removal receive Tamsulosin 0.4 mg plus either Tadalafil 5 mg or 2.5 mg and are followed for stent-related symptoms such as flank pain, urinary frequency, urgency, dysuria, hematuria, and sexual discomfort. The trial compares symptom burden and safety between the two tadalafil doses when used in combination with tamsulosin. Major exclusions include prior prostate or bladder surgery, significant cardiac disease, diabetes, kidney dysfunction, solitary kidney, neurological or oncologic conditions, recent pelvic radiation, or use of interacting medications. Outcomes focus on patient-reported symptom scores and adverse events during the stent dwell time.

Why it matters

Potential benefit: If successful, this combination could reduce stent-related symptoms and improve quality of life, possibly with fewer side effects or lower cost if the 2.5 mg dose proves effective.

How similar studies have gone: Previous studies suggest alpha-blockers and PDE5 inhibitors can reduce stent-related symptoms, but the combination of tamsulosin with a half-dose (2.5 mg) tadalafil has not been well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

\- patients older than 18 years of age, with presence of a double-J (DJ) stent (polyurethane) post endoscopic stone removal.

Exclusion Criteria:

* Patients younger than 18 years of age were excluded.
* Patients with a history of prostate or bladder surgery were excluded.
* Patients with prior lower urinary tract procedures were excluded.
* Patients with cancer were excluded.
* Patients with neurological conditions were excluded.
* Patients with a history of pelvic radiation were excluded.
* Patients with diabetes were excluded.
* Patients with kidney dysfunction (acute or chronic) were excluded.
* Patients with a solitary kidney were excluded.
* Patients with congenital urinary anomalies were excluded.
* Patients taking the following medications were excluded:

  * α-blockers
  * beta-blockers
  * calcium channel blockers
  * 5-alpha reductase inhibitors
  * PDE5 inhibitors
  * anticholinergics
  * nitrates
* Patients with cardiac issues were excluded.
* Patients with residual stone fragments after surgery were excluded.
* Patients with multiple or bilateral ureteral stones were excluded.
* Patients with long-term or bilateral stents requiring frequent changes were excluded.
* Patients with interstitial cystitis were excluded.
* Patients with chronic cystitis were excluded.
* Patients with prostatitis were excluded.
* Pregnant women were excluded.
* Breastfeeding women were excluded.
* Patients unavailable for follow-up were excluded.

Where it's running

  • Ain Shams University Hospital
    Cairo, Abbasia, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.